OmnaBio Inc. a Canadian CDMO dedicated to cell and gene therapy (CGT); has proposed the construction of a new 120,000 square foot centre of excellence based in Hamilton, Ontario. The centre will apply artificial intelligence (AI) and automation to increase CGT manufacturing capacity and supply for both North America and across the globe. It is also expected that access to and affordability of these biotherapies will be improved.

OmnaBio was Initially founded by Canada’s Centre for Commercialization of Regenerative Medicine (CCRM) and later partnered with MEDIPOST, Co., Ltd. At the new facility, MEDIPOST plans to manufacture CARTISTEM, which is an allogeneic (sourced from donor cells) umbilical cord blood-derived mesenchymal stem cell product used to treat knee cartilage defects in patients with osteoarthritis caused by degeneration.

The facility will be strategically positioned to optimise supply chain logistics, staff training, production flows and manufacturing processes.